The National Institute for Health and Clinical Excellence (NICE) has issued guidance (PDF) for using rimonabant (Acomplia®) for the treatment of obesity.
The guidance allows the use of rimonabant but only in patients for whom orlistat and sibutramine has proved inadequate, been poorly tolerated or is contraindicated. The guidance further qualifies that steatorrhoea associated with orlistat when not adhering to dietary advice is not considered as intolerance.
Action: NICE has clearly placed rimonabant as the third line treatment for obesity after orlistat and sibutramine. Clinicians should ensure that treatment of obesity reflects this advice.
|« HPV vaccine announced||Stronger warnings recommended for etoricoxib »|